Chronic myelogenous leukemia represents 7–20% of all leukemia cases, with a worldwide
incidence projected at less than one to two per 100,000 people. Approximately 85% of …

This book provides state-of-the-art reviews of key issues and recent developments relating
to chronic myeloid leukemia (CML), acquainting the reader with advances in research …

Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an
estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of …

The prognosis of patients with chronic myelogenous leukemia (CML) has significantly
improved over the last 20 years. Whereas the median survival durations were 4-5 years in …

Patients with chronic myeloid leukemia now have several potential treatment options from
which to choose. Imatinib mesylate currently provides excellent hematologic and cytogenetic …

The introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), has
revolutionized the treatment of chronic myeloid leukemia (CML). By directly targeting the Bcr …

Molecular discoveries and clinical advances over the past few decades have made the
treatment of chronic myeloid leukemia (CML) one of the great success stories of modern …

Abstract Learning Objectives After completing this course, the reader will be able to: Discuss
the rationale for using imatinib as front-line therapy for chronic phase CML. Interpret the …

Over the past 2 decades, our understanding of the pathobiological events underlying
chronic myelogenous leukemia (CML) has grown. At the same time, effective transplant and …

Chronic myeloid leukemia (CML) is sometimes mentioned as the disease of “firsts”. 1) It is
the first disease where the term “leukemia” was used. 2) It is the first neoplastic disorder …